<DOC>
	<DOCNO>NCT00004892</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different way may kill tumor cell . PURPOSE : Phase I trial study effectiveness O6-benzylguanine implant carmustine wafer treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>O6-Benzylguanine Carmustine Implants Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose O6-benzylguanine completely suppress AGT level patient recurrent malignant glioma . II . Evaluate safety tolerance increase duration 2 week continuously infuse O6-benzylguanine dose completely suppress tumor AGT activity combine intracranially implant polifeprosan 20 carmustine implant ( Gliadel wafer ) patient population . OUTLINE : This dose escalation study O6-benzylguanine ( O6-BG ) . Patients first cohort receive O6-BG IV 1 hour follow continuous infusion O6-BG 2 day prior surgery . Patients undergo surgical resection receive 8 polifeprosan 20 carmustine implant ( Gliadel wafer ) resect tumor cavity . Cohorts 14 patient receive escalate dos O6-BG 11 14 patient cohort complete suppression AGT level . Once dose O6-BG completely suppress AGT establish , subsequent patient receive O6-BG IV begin least 1 hour prior surgery follow establish continuous infusion dose begin day surgery . The infusion continue 14 day postoperatively . Cohorts 6-12 patient receive lengthen duration continuous infusion O6-BG maximum tolerate dose ( MTD ) determine length infusion reach 14 day . The MTD define dose precede 3 6 5 12 patient experience dose limit toxicity . Patients follow 3 , 6 , 9 , 12 month , death . PROJECTED ACCRUAL : A minimum 38 patient accrue study 9.5 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma determine prior stereotactic biopsy cytoreductive surgery removal supratentorial brain tumor Unilateral supratentorial tumor , measure least 1 cm , determine CT scan MRI No 1 focus tumor tumor cross midline Surgical treatment indicate baseline evaluation Received prior definitive ( great 5,000 cGy ) external beam radiotherapy 3 month ago Evidence progression At time tumor resection Gliadel wafer implantation : Intraoperative pathological diagnosis frozen section squash preparation malignant glioma OR Glioblastoma multiforme anaplastic astrocytoma permanent section prior surgery intraoperative pathological diagnosis frozen section squash preparation tumor , glioma , malignant glioma ( necrosis ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 60 day Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal Renal : Creatinine great 1.7 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year surgery No concurrent significant life threaten disease No known hypersensitivity nitrosoureas No malignancy past five year except curatively treat carcinoma situ cervix basal cell carcinoma skin PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover No concurrent chemotherapy first 56 day study Endocrine therapy : No concurrent dexamethasone antiemetic Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>